Table 2. 6MWT performance, hematological and clinical factors according to the presence of silent infarct; results are median (range) unless otherwise indicated.
| WHOLE COHORT | UNTRANSFUSED PATIENTS | |||||
| Silent Infarct | No Silent Infarct | p value | Silent Infarct | No Silent Infarct | p value | |
| Number of patients | 12 | 34 | 5 | 32 | ||
| Age (years) | 11.8 (9.2–16.2) | 13.0 (6.1–19.7) | 0.37 | 13 (9.2–16.2) | 13 (6.1–19.7) | 0.86 |
| Male gender, n (%) | 7 (58.3%) | 13 (38.2%) | 0.23 | 1 (20%) | 12 (37.5%) | 0.64 |
| 6MWT (% PV) | 74.9 (63.8–86.9) | 86.0 (79.1–92.1) | 0.04 | 64.0 (44.7–84.2) | 86.0 (66.3–105.2) | 0.003 |
| Haemoglobin (g/dl) | 9.7 (8.3–10.5) | 8.8 (6.7–12.2) | 0.06 | 9.0 (8.3–10.5) | 8.8 (6.7–12.2) | 0.45 |
| Haemoglobin fœtal (% Hb total) | 2.5 (0.2–16.0) | 15.0 (0.2–27.8) | <0.001 | 11.7 (1.8–24.0) | 15.0 (4.1–27.8) | 0.09 |
| MVC (fL) | 86.3 (75.5–98.0) | 94.7 (64.0–115.0) | 0.009 | 86.3 (81.0–98.0) | 94.7 (64.0–115.0) | 0.21 |
| Polynuclear Neutrophils (103/µL) | 6.9 (2.5–8.4) | 4.2 (1.4–5.7) | 0.01 | 2.8 (2.5–5.5) | 4.2 (1.5–5.7) | 0.42 |
| Reticulocytes (103/µL) | 273 (133–511) | 329 (120–491) | 0.55 | 273 (155–511) | 311 (120–466) | 0.74 |
| LDH (UI/L) | 945 (382–1092) | 825 (406–1400) | 0.83 | 927 (406–1026) | 831 (382–1400) | 0.91 |
| AST (UI/L) | 42 (23–46) | 36 (18–66) | 0.85 | 42 (20–46) | 36 (18–66) | 0.64 |
| HbSS/Sβ0, n (%) | 11 (91.7%) | 32 (94.1%) | 0.77 | 4 (80%) | 30 (93.8%) | 0.36 |
| ACS | 11 (91.7%) | 27 (79.4%) | 0.42 | 4 (80%) | 25 (78.2%) | 1.00 |
| VOC | 1 (0–9) | 1 (0–10) | 0.62 | 0 (0–9) | 1 (0–10) | 0.56 |
| Hydroxyurea treatment, n (%) | 9 (75.0%) | 33 (97.1%) | 0.02 | 4 (80%) | 31 (96.9%) | 0.56 |
| Chronic tranfusion program, n (%) | 7 (58.3%) | 2 (5.9%) | <0.001 | 0 | 0 | NA |
6MWT, 6-Minute Walk Test; %PV = per cent of the predicted value; MCV, Mean Cell Volume; LDH, Lactate Dehyrogenase; AST, Aspartate Transaminase; ACS, Acute Chest Syndrome; VOC, Vaso-Occulsive Crisis having required an hospitalisation during the last 4 years.